Volume 8, Issue 1 (2023)
SJMR 2023, 8(1): 73-81 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Talebian N. Investigation of Various Factors on Ovarian Cancer: A Review Study. SJMR 2023; 8 (1) : 8
URL: http://saremjrm.com/article-1-293-en.html
URL: http://saremjrm.com/article-1-293-en.html
Sarem Gynecology, Obstetrics and Infertility Research Center, Sarem Women’s Hospital, Iran University of Medical Science (IUMS), Tehran, Iran.
Abstract: (3195 Views)
Introduction: Ovarian cancer is a type of cancer that starts from the ovary. This disease leads to the creation of abnormal cells that have the ability to invade or spread to other parts of the body. At the beginning of this process, the symptoms may be vague or non-obvious, but as the cancer progresses, the symptoms become more likely. Ovarian cancer patients usually do not have specific symptoms and often go to the doctor with non-specific symptoms such as bloating, pelvic pain, abdominal swelling and other symptoms. Several factors can increase the risk of developing ovarian cancer, including genetic factors, age, use of hormone therapy after menopause, infertility, obesity has been identified as a possible risk factor. Ovarian cancer is 1 in 75 in a woman's lifetime and the chance of her dying from this disease is 1 in 1004. This disease usually shows itself in the final stages, with a 5-year relative survival rate of only 29%. Despite its global health importance, the cause of this deadly disease is not fully understood. Ovarian cancer is the fifth cause of cancer-related death in women and the deadliest female malignancy. The aim of this article is to provide a comprehensive overview of general epidemiology.
Conclusion: The possibility of ovarian cancer should be considered for any woman who presents with new and persistent diseases. Ovarian cancer should always be treated according to published guidelines. Appropriate treatment of primary ovarian cancer includes removal of the primary tumor and all macroscopically visible tumor mass, as well as careful inspection. The natural history of ovarian cancer shows that it remains a tumor that takes the lives of women of reproductive age for decades to come. If ovarian cancer is in the early stages and is treated, it may be curable. Treatment usually involves a combination of radiation therapy or chemotherapy. The outcome of the treatment depends on these factors: the extent of the disease and the subtype of cancer, which the person is suffering from. Overall, the five-year survival rate in the United States is about 45 percent. The results are worse in developing countries. Researchers are constantly looking for clues, such as lifestyle, diet, and medications that may change the risk of ovarian cancer. Identification of more accurate molecular biomarkers for early detection of ovarian cancer is an important unmet medical need. CA125 is still the best and most widely used biomarker for early detection of ovarian cancer used in clinics, but it is very limited.
Conclusion: The possibility of ovarian cancer should be considered for any woman who presents with new and persistent diseases. Ovarian cancer should always be treated according to published guidelines. Appropriate treatment of primary ovarian cancer includes removal of the primary tumor and all macroscopically visible tumor mass, as well as careful inspection. The natural history of ovarian cancer shows that it remains a tumor that takes the lives of women of reproductive age for decades to come. If ovarian cancer is in the early stages and is treated, it may be curable. Treatment usually involves a combination of radiation therapy or chemotherapy. The outcome of the treatment depends on these factors: the extent of the disease and the subtype of cancer, which the person is suffering from. Overall, the five-year survival rate in the United States is about 45 percent. The results are worse in developing countries. Researchers are constantly looking for clues, such as lifestyle, diet, and medications that may change the risk of ovarian cancer. Identification of more accurate molecular biomarkers for early detection of ovarian cancer is an important unmet medical need. CA125 is still the best and most widely used biomarker for early detection of ovarian cancer used in clinics, but it is very limited.
Article number: 8
Article Type: Analytical Review |
Subject:
Women Diseases
Received: 2023/11/8 | Accepted: 2023/11/8 | Published: 2023/11/8
Received: 2023/11/8 | Accepted: 2023/11/8 | Published: 2023/11/8
References
1. Colvin, Caroline Wingo; Abdullatif, Hussein (2013). The clinical relevance of developmental changes in the reproductive system". Clinical Anatomy. 26 (1): 115-129 [DOI:10.1002/ca.22164]
2. Cannistra SA, et al, Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. Cancer: Principles and Practice of Oncology. 2015
3. Doherty JA, Jensen A, Kelemen LE et al. Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research. JNCI: Journal of the National Cancer Institute. 2017; 109 (10).
4. Fleming GF, Seidman JD, Yemelyanova A and Lengyel E. (2017). Chapter 23: Epithelial Ovarian Cancer. In D. S. Chi, A. Berchuck, D. S. Dizon, & C. M. Yashar (Authors), Principles and practice of gynecologic oncology
5. Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004. Cancer Epidemiol Biomarkers Prev. 2009;18(1):132-139. [DOI:10.1158/1055-9965.EPI-08-0771]
6. Epidemiology of ovarian cancer. Patricia Gaona-Luviano, Lourdes Adriana Medina-Gaona, Kassandra Magaña-PérezAccepted for publication Jun 17, 2020, 20-34
7. Rebbeck TR, Kauff ND, Domchek SM: Meta-analysis of risk reduc -tion estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101(2): 80-7 [DOI:10.1093/jnci/djn442]
8. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2021, 71, 209-249. [DOI:10.3322/caac.21660]
9. Jayson, G.C.; Kohn, E.C.; Kitchener, H.C.; Ledermann, J.A. Ovarian cancer. Lancet 2014, 384, 1376-1388. [DOI:10.1016/S0140-6736(13)62146-7]
10. Tung KH, Wilkens LR, Wu AH, McDuffie K, Nomura AM, Kolonel LN, et al. Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J Epidemiol. 2005; 161: 321-9. [DOI:10.1093/aje/kwi046]
11. Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ, Cramer DW. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16: 30-5 [DOI:10.1158/1055-9965.EPI-06-0688]
12. Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand. 2004; 83: 783-95 [DOI:10.1111/j.0001-6349.2004.00550.x]
13. Epidemiology of ovarian cancer: a review. Brett M. Reid, Jennifer B. Permuth, Thomas A. SellersCancer Biol Med 2017. doi: 10.20892/j.issn.2095-3941
14. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018;68:284-96 [DOI:10.3322/caac.21456]
15. Ovarian Cancer. Burges A, Schmalfeldt B: Ovarian cancer: diagnosis and treatment. Dtsch Arztebl Int 2011; 108(38): 635-41.
16. Trimbos JB, et al.: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 2003; 95(2): 113-25. [DOI:10.1093/jnci/95.2.113]
17. Rebbeck TR, Kauff ND, Domchek SM: Meta-analysis of risk reduc -tion estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101(2): 80-7 [DOI:10.1093/jnci/djn442]
18. Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proceedings of the National Academy of Sciences. 2014; 111(39):14205-10. [DOI:10.1073/pnas.1415979111]
19. Hoogerbrugge N, Jongmans MCJ. Finding all BRCA pathogenic mutation carriers: best practice models. Eur J Hum Genet. 2016; 24(S1):S19-S26. [PubMed: 27514840] [DOI:10.1038/ejhg.2016.95]
20. New insights into ovarian cancer pathology. J. Prat, Volume 23 | Supplement 10 | September 2012 [DOI:10.1093/annonc/mds300]
21. World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.12
22. Piek JM, van Diest PJ, Verheijen RH (2008). "Ovarian carcinogenesis: an alternative hypothesis". Adv. Exp. Med. Biol. Advances in Experimental Medicine and Biology. 622: 79 [DOI:10.1007/978-0-387-68969-2_7]
23. Ovarian Epithelial Cancer Treatment (PDQ®)". NCI. 2014-05-12. Retrieved 1 July 2014.
24. Schmeler KM, Lu KH. Gynecologic cancers associated with Lynch syndrome/HNPCC. Clinical and Translational Oncology. 2008; 10(6):313-7 [DOI:10.1007/s12094-008-0206-9]
25. Watson P, Vasen HFA, Mecklin JP, Bernstein I, Aarnio M, Järvinen HJ, et al. The Risk of Extracolonic, Extra-endometrial Cancer in the Lynch Syndrome. International journal of cancer Journal international du cancer. 2008; 123(2):444-9 [DOI:10.1002/ijc.23508]
26. Ovarian cancer prevention in high risk women. Sarah M. Temkin, Jennifer Bergstrom, Goli Samimi, Clin Obstet Gynecol. 2017 December ; 60(4): 738-757 [DOI:10.1097/GRF.0000000000000318]
27. Herráez Á (2012) Biología Molecular e Ingeniería Genética 2nd ed (España: Elsevier) pp 449-479 chapter 26 (Bases Moleculares del Cáncer)
28. Natural history of ovarian cancer. Mexican Institute of Social Security (IMSS), Reforma 476, Cuauhtémoc, Juárez, 06600 Distrito Federal, México City, México 2014, 8:465
29. Shin A, Song YM, Yoo KY, Sung J. Menstrual factors and cancer risk among Korean women. Int J Epidemiol. 2011; 40: 1261-8. [DOI:10.1093/ije/dyr121]
30. Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL. Age at menarche and risk of ovarian cancer: A meta-analysis of epidemiological studies. Int J Cancer. 2013; 132: 2894-900. [DOI:10.1002/ijc.27952]
31. Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer. 2011; 105: 1436-42 [DOI:10.1038/bjc.2011.371]
32. McGowan L, Norris HJ, Hartge P, Hoover R, Lesher L. Risk factors in ovarian cancer. Eur J Gynaecol Oncol. 1988; 9: 195-9. 112Shin A, Song YM, Yoo KY, Sung J. Menstrual factors and cancer risk among Korean women. Int J Epidemiol. 2011; 40: 1261-8 [DOI:10.1093/ije/dyr121]
33. Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL. Age at menarcheand risk of ovarian cancer: A meta-analysis of epidemiological studies. Int J Cancer. 2013; 132: 2894-900 [DOI:10.1002/ijc.27952]
34. He CY, Kraft P, Chen C, Buring JE, Paré G, Hankinson SE, et al.Genome-wide association studies identify loci associated with ageat menarche and age at natural menopause. Nat Genet. 2009; 41:724-8. [DOI:10.1038/ng.385]
35. Weiderpass E, Sandin S, Inoue M, Shimazu T, Iwasaki M, Sasazuki S, et al. Risk factors for epithelial ovarian cancer in Japan - results from the Japan Public Health Center-based Prospective Study cohort. Int J Oncol. 2012; 40: 21-30.
36. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol. 2002; 156: 363-73 [DOI:10.1093/aje/kwf048]
37. Schoenaker DAJM, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int J Epidemiol. 2014; 43: 1542-62 [DOI:10.1093/ije/dyu094]
38. Shi J, Zhang B, Choi JY, Gao YT, Li H, Lu W, et al. Age at menarche and age at natural menopause in East Asian women: a genome-wide association study. Age. 2016; 38: 513-23. [DOI:10.1007/s11357-016-9939-5]
39. He CY, Kraft P, Chen C, Buring JE, Paré G, Hankinson SE, et al. Genome-wide association studies identify loci associated with age at menarche and age at natural menopause. Nat Genet. 2009; 41:724-8.48- [DOI:10.1038/ng.385]
40. Publishing، Harvard Health. «Low-dose aspirin and ovarian cancer risk». Harvard Health. 2019.7.25.
41. 41-Ovarian cancer prevention in high risk women. Sarah M. Temkin, MD*Clin Obstet Gynecol. 2017 December; 60(4): 738-757. [DOI:10.1097/GRF.0000000000000318]
42. 42-Molecular Biomarkers for the Early Detection of Ovarian Cancer. Ruiqian Zhang † , Michelle K. Y. Siu †, Hextan Y. S. Ngan and Karen K. L. Chan * Int. J. Mol. Sci. 2022, 23, 12041. [DOI:10.3390/ijms231912041]
43. Høgdall, E.V.S.; Christensen, L.; Kjaer, S.K.; Blaakaer, J.; Kjærbye-Thygesen, A.; Gayther, S.; Jacobs, I.J.; Høgdall, C.K. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA"Ovarian Cancer Study. Gynecol. Oncol. 2007, 104, 508-515 [DOI:10.1016/j.ygyno.2006.09.028]
44. Sturgeon, C.M.; Duffy, M.J.; Walker, G. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: The pivotal role of the clinical laboratory. Ann. Clin. Biochem. 2011, 48, 295-299 [DOI:10.1258/acb.2011.011117]
45. A label-free dual immunosensor for the simultaneous electrochemical determination of CA125 and HE4 biomarkers for the early diagnosis of ovarian cancer. MelikeBilgiKamaç, MuhammedAltun, MerveYilmaz & Mustafa Kemal Sezgintürk. Analytical and Bioanalytical Chemistry volume 415, pages1709-1718 (2023) [DOI:10.1007/s00216-023-04569-y]
46. Zapardiel, I.; Diestro, M.D.; Aletti, G. Conservative treatment of early stage ovarian cancer: Oncological and fertility outcomes. Eur. J. Surg. Oncol. 2014, 40, 387-393 [DOI:10.1016/j.ejso.2013.11.028]
47. Colombo, N.; Sessa, C.; Bois, A.D.; Ledermann, J.; McCluggage, W.G.; McNeish, I.;Morice, P.; Pignata, S.; Ray-Coquard, I.;Vergote, I.; et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, earlyand advanced stages, borderline tumours and recurrent disease. Ann. Oncol. 2019, 30, 672-705. [DOI:10.1136/ijgc-2019-000308]
48. Havrilesky, L.J.; Sanders, G.D.; Kulasingam, S.; Myers, E.R. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Gynecol. Oncol. 2008, 111, 179-187. [DOI:10.1016/j.ygyno.2008.07.006]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
